Added to YB: 2026-04-27
Pitch date: 2026-01-29
GRCE [bullish]
Grace Therapeutics, Inc.
-35.03%
current return
Author Info
Alpha Talon Investment Research is a Hong Kong–based private family office deploying only proprietary capital across biotech, value turnarounds, and catalyst-driven shorts, focused on intrinsic value, regulatory odds, and mispriced fundamentals. Sign up for the newsletter.
Company Info
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
Market Cap
$66.7M
Pitch Price
$3.54
Price Target
11.00 (+378%)
Dividend
N/A
EV/EBITDA
-4.27
P/E
-11.28
EV/Sales
N/A
Sector
Pharmaceuticals
Category
special_situation
Grace Therapeutics, Inc. (GRCE): When Execution, Not Biology, Drives Value
GRCE: Single-asset IV nimodipine (GTx-104) for aSAH w/ Apr 23, 2026 PDUFA. Addresses real-world oral delivery failures in neuro-ICU: 54% dose completion vs 8% oral, 19% less hypotension. 505(b)(2) pathway de-risks biology; CMC is main risk. $100-120M U.S. peak sales at $750-1200/dose, 7-10 day use. $21M cash, no launch capital. Strategic monetization likely via partnership/acquisition. PT $11 on 80% approval probability.
Read full article (29 min)